Literature DB >> 18381093

Childhood immune thrombocytopenic purpura: diagnosis and management.

Victor Blanchette1, Paula Bolton-Maggs.   

Abstract

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low circulating platelet count caused by destruction of antibody-sensitized platelets in the reticuloendothelial system. ITP can be classified as childhood versus adult, acute versus chronic, and primary versus secondary. Persistence of thrombocytopenia defines the chronic form of the disorder. Secondary causes of ITP include collagen vascular disorders, immune deficiencies, and some chronic infections. This review focuses on the diagnosis and management of children who have acute and chronic ITP. Emphasis is placed on areas of controversy and new therapies.

Entities:  

Mesh:

Year:  2008        PMID: 18381093     DOI: 10.1016/j.pcl.2008.01.009

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  9 in total

1.  Management of immune thrombocytopenic purpura: an update.

Authors:  Rajasekharan Warrier; Aman Chauhan
Journal:  Ochsner J       Date:  2012

Review 2.  Childhood immune thrombocytopenia: Clinical presentation and management.

Authors:  Mohamed El Faki Osman
Journal:  Sudan J Paediatr       Date:  2012

Review 3.  Management of immune thrombocytopenic purpura in children: potential role of novel agents.

Authors:  Amy Lee Bredlau; John W Semple; George B Segel
Journal:  Paediatr Drugs       Date:  2011-08-01       Impact factor: 3.022

4.  Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy.

Authors:  Federica Bertuola; Carla Morando; Francesca Menniti-Ippolito; Roberto Da Cas; Annalisa Capuano; Giorgio Perilongo; Liviana Da Dalt
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

5.  One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab.

Authors:  Brigitta U Mueller; Carolyn M Bennett; Henry A Feldman; James B Bussel; Thomas C Abshire; Theodore B Moore; Hadi Sawaf; Mignon L Loh; Zora R Rogers; Bertil E Glader; Maggie C McCarthy; Donald H Mahoney; Thomas A Olson; Stephen A Feig; Adonis N Lorenzana; William C Mentzer; George R Buchanan; Ellis J Neufeld
Journal:  Pediatr Blood Cancer       Date:  2009-02       Impact factor: 3.167

6.  Hemorrhagic Stroke in an Adolescent Female with HIV-Associated Thrombotic Thrombocytopenic Purpura.

Authors:  Natella Rakhmanina; Edward Cc Wong; Jeremiah C Davis; Patricio E Ray
Journal:  J AIDS Clin Res       Date:  2014-06

7.  Treatment of immune thrombocytopenic purpura: focus on eltrombopag.

Authors:  Lawrence Rice
Journal:  Biologics       Date:  2009-07-13

8.  Health-related quality of life in children with chronic immune thrombocytopenia in China.

Authors:  Heng Zhang; Li Wang; Meijie Quan; Jie Huang; Peng Wu; Qin Lu; Yongjun Fang
Journal:  Health Qual Life Outcomes       Date:  2016-03-15       Impact factor: 3.186

9.  Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination.

Authors:  Andrew Jay Portuguese; Cassandra Sunga; Rebecca Kruse-Jarres; Terry Gernsheimer; Janis Abkowitz
Journal:  Blood Adv       Date:  2021-07-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.